Twist Bioscience 投研报告

$Twist Bioscience(TWST.US) is a biotechnology company headquartered in San Francisco, USA, founded in 2013, focusing on DNA synthesis through high-throughput silicon-based platforms. Its core technology lies in using silicon chips instead of traditional plastic plates, significantly improving DNA synthesis efficiency and reducing costs. Compared to traditional phosphoramidite chemical column synthesis methods, Twist's approach can achieve a million-fold reduction in volume, a thousand-fold increase in throughput, and improve synthesis accuracy.

The company's main businesses include:

• Synthetic gene fragments and gene cloning services
• Large-scale oligonucleotide pools (Oligo Pools)
• NGS (high-throughput sequencing) library construction products and probe kits
• Antibody discovery and optimization platform services
• DNA data storage research platform (cutting-edge layout)

Twist's customers cover a wide range, including pharmaceutical companies, research institutions, agricultural technology companies, and diagnostic reagent companies. The company went public on NASDAQ in 2018 (ticker: TWST), becoming one of the few publicly traded companies in the gene synthesis field.

Key milestones include:

• 2016: Launched its first product, synthetic genes and oligonucleotide pools
• 2018: Successfully listed on NASDAQ
• 2021: Acquired Abveris to strengthen its antibody business platform
• Post-2022: Invested in "Future Factory" to expand production capacity and explore enzymatic DNA synthesis and DNA data storage

II. Financial Analysis (2020–2023 Fiscal Years)

Key observations:

• Rapid revenue growth with a CAGR exceeding 40%
• Steady improvement in gross margin, estimated to reach 43% in 2024
• Continued losses, but R&D investments expand technological moat
• Cash reserves exceeded $300 million by the end of 2023, providing ample funds for mid-term development

III. Market Positioning and Customer Structure

Twist Bioscience holds a "key upstream tool provider" position in the synthetic biology industry chain. Its products serve as foundational inputs, supporting downstream drug development, diagnostic reagent development, agricultural transformation, and biomaterial synthesis.

Customer types:

• Biopharmaceutical companies (antibody drugs, vaccine development)
• Academic research institutions (e.g., Harvard, MIT, Stanford)
• Synthetic biology startups (e.g., Ginkgo Bioworks)
• Agricultural technology companies (transgenic microorganism research)
• Genetic testing companies (cancer panels, liquid biopsies)

The number of customers increased from 2,200 in 2020 to over 3,500 in 2024, with approximately one-third coming from outside the U.S., with rapid growth in Asia and Europe.

IV. Technological Advantages and Barriers

Twist's core technological barriers include:

1. Silicon-based chip synthesis platform: Each chip can synthesize millions of oligonucleotides, with throughput thousands of times higher than traditional column synthesis.
2. Inkjet synthesis technology: Precisely controls reaction microdots, with an error rate below one in a thousand.
3. Smaller reaction volume on silicon chips: Saves reagents and significantly reduces per-base synthesis costs.
4. Intellectual property and patent portfolio: Covers micro-array design, chemical processes, and splicing algorithms.
5. Customer network and data accumulation barrier: Data from thousands of customers optimizes production processes, improving success rates and accuracy.
6. New technology reserves: Actively developing enzymatic DNA synthesis and DNA storage technologies for next-generation platforms.

V. Competitive Landscape Analysis

The DNA synthesis market where Twist Bioscience operates features a technology-driven oligopolistic competition.

Main competitors:

• IDT (Integrated DNA Technologies): Traditional market leader with stable products and higher prices.
• GenScript: Strong in the Asian market with a broad customer base.
• BBI Life Sciences: Cost advantages in the Chinese domestic market.
• Ginkgo Bioworks: A synthetic biology platform company, previously a major customer of Twist, now partially self-sufficient in synthesis capabilities.
• DNA Script, Evonetix and other startups: Developing enzymatic and MEMS platforms with potential disruptive capabilities.

Through cost-effectiveness, scalability, and continuous innovation, Twist has secured a leading position in the U.S. market, with international expansion accelerating.

VI. Risk Factors

1. Regulatory and biosafety risks: Synthetic DNA could be used for illegal purposes, and stricter regulations may increase compliance costs.
2. Technological substitution risks: Successful commercialization of enzymatic synthesis or other new technologies could disrupt existing advantages.
3. Financial pressure and continued losses: Not yet profitable, relying on capital market support.
4. Customer volatility risks: Budget cuts from research customers or loss of major clients could cause revenue fluctuations.
5. Price wars and industry competition: If established players cut prices to capture market share, Twist's profit margins could be squeezed.
6. Business execution risks: New business segments like antibody screening and DNA storage face commercialization uncertainties.

VII. Analyst Ratings and Market Expectations

Latest Views:

• TD Cowen: Lowered target price to $36, maintained Buy
• Evercore ISI: Maintained Outperform, target $46
• JPMorgan: Maintained Underweight, target $25

Analysts generally believe the company:

• Has clear long-term logic and is strategically positioned upstream
• Will see significant gross margin improvement in 2024
• Has not yet confirmed a profit turning point, with continued losses

VIII. Investment Recommendations

Rating recommendation: Long-term accumulation, short-term observation

Suitable for investors:

• ✔ Growth-oriented, focusing on technological moats and industry trends
• ✔ Able to withstand short-term volatility, willing to wait 2–3 years for profit realization

Core reasons:

• Broad industry prospects with rapidly growing DNA synthesis demand
• Globally leading technology with a deep moat as a platform provider
• Gross margin has rebounded to 43%, with potential for further improvement
• Profitability may emerge in 2026
• Current valuation (P/S ~7x) is acceptable

For participation, it is recommended to build positions gradually, monitor profit and cash flow improvement, and closely watch industry technology iterations.